Knowthestock.com
AXGT - Axovant Gene Therapies Ltd.
We couldn't determine Recommendation based on the data we have.




Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Axovant Gene Therapies Ltd. (AXGT) - http://www.axovant.com
Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.
Exchange - NASDAQ
Industry - Biotechnology
Sector - Health Technology
CEO - Pavan Cheruvu
Employees - 38
    Close


Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.